Asia Pacific Antidepressant Drugs Market Size study, by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others) by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others) and Country Forecasts 2022-2032
Asia Pacific Antidepressant Drugs Market is valued approximately USD 4.17 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.55% over the forecast period 2024-2032. Antidepressants are common prescription medications that can help treat depression and other conditions such as anxiety and obsessive-compulsive disorder. Healthcare providers prescribe them to treat other conditions such as depression and other mental condition. These drugs work by affecting the levels of certain chemicals in the brain, such as norepinephrine and serotonin. Furthermore, awareness of mental health issues is rising in many countries in Asia Pacific region, which is leading to demand for mental health services and treatments, including antidepressant medications in the Asia Pacific Antidepressant Drugs Market.
The Asia Pacific Antidepressant Drugs Market is driven by rising healthcare spending, leading to greater access to healthcare services and pharmaceuticals, including antidepressant medications. across the region. Moreover, rising prevalence of metal disorders such as Depression and other mental health disorders in the APAC region, and rising geriatric population in the region is driving demand for antidepressant medications. In addition, rising government support and rising drug approval activities in the region is creating new opportunities to the market growth. However, availability of alternative mode of treatment and limited reimbursement policy in the region is going to impede the overall demand for the market during the forecast period 2024-2032.
The key Countries considered for the Asia Pacific Antidepressant Drugs market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market in terms of revenue owing to factors such as rising prevalence of mental disorders, rising healthcare expenditure, rising drug development, research and drug approval activities across the region. Furthermore, the market in India, on the other hand, is expected to develop at the fastest rate over the forecast period 2024-2032.
Major market player included in this report are:Mayne Pharma Group Limited
Aurobindo Pharma Ltd
Wockhardt Limited
Currax Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Limited,
Jiangsu Hengrui Pharmaceuticals Company Ltd.,
Takeda Pharmaceuticals Ltd
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below: By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others
By Depressive Disorders:
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Years considered for the study are as follows:Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.